Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Coeptis Therapeutics Holdings (COEPW) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Coeptis Therapeutics Holdings' Operating Expenses rose 2463.01% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 2064.91%. This contributed to the annual value of $10.1 million for FY2024, which is 5321.56% down from last year.
  • Per Coeptis Therapeutics Holdings' latest filing, its Operating Expenses stood at $2.7 million for Q3 2025, which was up 2463.01% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, Coeptis Therapeutics Holdings' Operating Expenses ranged from a high of $15.7 million in Q1 2022 and a low of $2.1 million during Q3 2024
  • Moreover, its 4-year median value for Operating Expenses was $3.7 million (2023), whereas its average is $5.1 million.
  • In the last 5 years, Coeptis Therapeutics Holdings' Operating Expenses crashed by 7289.29% in 2024 and then soared by 6536.67% in 2025.
  • Quarter analysis of 4 years shows Coeptis Therapeutics Holdings' Operating Expenses stood at $3.0 million in 2022, then grew by 10.6% to $3.4 million in 2023, then crashed by 35.76% to $2.2 million in 2024, then grew by 23.45% to $2.7 million in 2025.
  • Its Operating Expenses stands at $2.7 million for Q3 2025, versus $4.7 million for Q2 2025 and $4.1 million for Q1 2025.